Xenetic Biosciences, Inc. Appoints Guenther Koehne to the Scientific Advisory Board
May 01, 2019
Share
Xenetic Biosciences, Inc. announced that it has appointed Guenther Koehne, M.D., Ph.D. to the company's Scientific Advisory Board. Dr. Guenther Koehne is an internationally recognized cancer specialist and current Chief of Blood & Marrow Transplant and Hematologic Oncology at the Miami Cancer Institute. He has over 30 years of extensive experience in the treatment of leukemia, myelodysplastic syndrome, multiple myeloma and other lymphoproliferative diseases, including with autologous and allogeneic stem cell transplantations. Over the course of his career, he has established a noteworthy reputation for his work in adoptive immunotherapeutic approaches with antigen-specific, donor-derived T lymphocytes in the treatment of viral complications following allogeneic transplants and has developed new approaches to the treatment of patients with high-risk multiple myeloma, minimal residual disease of leukemia and relapsed disease post-allogeneic bone marrow transplantation.
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.